Extensive Study on the Current Landscape of the Evolving Pipeline of Ubiquitin Enzyme Inhibitors and Offers a Comprehensive Discussion on the Future Potential of this Market 2016-2030 - Research and Markets
DUBLIN, Dec 22, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report to their offering.
The "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report provides an extensive study on the current landscape of the evolving pipeline of ubiquitin enzyme inhibitors and offers a comprehensive discussion on the future potential of this market.
The ubiquitin proteasome system (UPS) is one of the key protein degradation pathway involved in the control of protein homeostasis and turnover that mediates the regulation of several cellular processes. The UPS consists of two separate consecutive steps, ubiquitination and proteasomal degradation. Due to its involvement in multiple metabolic and regulatory functions, the UPS is considered as a vital part of the cellular machinery controlling protein homeostasis.
Ubiquitin enzymes have been implicated in various cellular processes, such as protein homeostasis, apoptosis, autophagy, DNA damage repair, cell cycle control and senescence. Due to their involvement in multiple metabolic and regulatory functions, any deviations in the normal functioning of the UPS has been shown to lead to the development of diverse types of diseases.
Initial research on the UPS led to the development of several proteasome inhibitors, such as Velcade®, Kyprolis® and Ninlaro®, which are already available in different regions across the globe. However, since these drugs target the entire protein degradation pathway, lack of target specificity renders them potentially harmful and their use has been shown to pose side effects in patients.
Consequently, the focus is gradually shifting from proteasome inhibitors to targeting specific components of the UPS, primarily on ubiquitination enzymes. This is a relatively new segment of the overall market. With no marketed products, the UPS associated enzyme inhibitors/modulators market is still in its infancy. The report primarily focuses on four classes of enzymes that have been shown to possess therapeutic relevance; these include E1 activating enzymes, E2 conjugating enzymes, E3 ligases and deubiquitinases (DUBs).
Among other elements, the report provides the following information:
- The current state of the market with respect to the key players, phase of development of pipeline products (both clinical and preclinical/discovery), target enzyme classes and the key disease indications.
- Comprehensive profiles highlighting clinical trial details, key preclinical/clinical findings and future market opportunity for the clinical stage (phase I/II, phase II and phase III) ubiquitin enzyme inhibitors.
- Various investments and grants received by companies focused in this area in order to accelerate and support their R&D activities.
- Partnerships that have taken place in the recent past covering product development/commercialization agreements, research collaborations, clinical trial collaborations, license agreements, acquisitions and other such deals between stakeholders in the industry.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Ubiquitin Enzyme Inhibitors: Market Overview
5. Key Insights: Therapeutic Areas and Potential Targets
6. E1 and E2 Enzymes as Therapeutic Targets
7. E3 Enzymes as Therapeutic Targets
8. DUB Enzymes as Therapeutic Targets
9. Associated Drug Classes
10. Venture Capital Interest
11. Recent Collaborations
12. Market Forecast and Opportunity Analysis
13. Conclusion
14. Interview Transcripts
15. Appendix 1: Tabulated Data
16. Appendix 2: List Of Companies And Organizations
Companies Mentioned
- 3SBio
- 5AM Ventures
- ARCH Venture Partners
- Abbiotec
- Abcam
- AcelRx Pharmaceuticals
- Aegera Therapeutics
- Aeneas Ventures
- Agilis Biotherapeutics
- Aileron Therapeutics
- Aju IB Investment
- Alexion Pharmaceuticals
- Almac Discovery
- Amgen
- Angelman Syndrome Foundation
- Apeiron Biologics
- Apple Tree Partners
- Arcus Ventures
- Argenta Discovery
- Argos Soditic
- Arvinas
- Ascenta Therapeutics
- Ascentage Pharma
- Astellas Venture Management
- Astex Pharmaceuticals
- AstraZeneca
- Australasian Leukemia and Lymphoma Group
- Avacta
- BPS Biosciences
- Bavarian Research Foundation
- Bio-Techne
- BioTheryx
- Biogen
- Biogenova
- Biotechnology and Biological Sciences Research Council
- Boehringer Ingelheim
- Boston Biochem
- Boston University Technology Development...
- BostonBiochem
- Business Development Bank of Canada
- Business Development Corporation (BDC) Capital
- C4 Therapeutics
- CMEA Ventures
- Calculus Capital
- Canaan Partners
- Cancer Research Technology
- Captor Therapeutics
- Carmot Therapeutics
- Cayman Chemicals
- Celgene Corporation
- Cell Signaling Technology
- CellCentric
- CellXplore
- Cellivery Therapeutics
- Celon Laboratories
- Chinese University of Hong Kong
- Cisbio Bioassays
- Clarus Ventures
- Cleave Biosciences
- Cobro Ventures
- Columbia University
- Comprehensive Cancer Center of Wake Forest University
- Connecticut Innovations
- Cormorant Asset Management
- Curis
- Cyclofluidic
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- Debiopharm
- Desjardins Venture Capital
- Deutsche Bank
- Domain Associates
- Dr. Reddy's
- Draper Esprit
- Draper Fisher Jurvetson
- E3X Bio
- EG Capital Group
- Edmond de Rothschild Investment Partners
- Elan Pharmaceuticals
- Elm Street Ventures
- Encycle Therapeutics
- Endeavour Vision
- Ensemble Therapeutics
- Enterprise Partners
- Enzo Lifesciences
- Erimos Pharmaceutical
- Excel Venture Management
- F-Prime Capital Partners
- Flagship Ventures
- Focus Biomolecules
- Forma Therapeutics
- Foundation Venture Capital Group
- Foundation for Angelman Syndrome Therapeutics (FAST)
- Fox Chase Cancer Center
- Francis Crick Institute
- Genentech (Hoffmann-La Roche)
- GlaxoSmithKline
- GrowthWorks Capital
- Halle University
- Harris & Harris Group
- Harvard Medical School
- Hasso Plattner Ventures
- Hatteras Venture Partners
- HealthCare Ventures
- Horizon Discovery
- Human Genome Sciences
- Hybrigenics
- IP Group
- Imperial Innovations
- Index Ventures
- Innovate UK
- Intrexon
- Invenio Therapeutics
- Investissement Québec
- Janssen Research & Development
- Kamiya Biomedical Company
- Karolinska Institute
- Laboratorio Varifarma
- Latterell Venture Partners
- Life Technologies
- LifeSensors
- Ligand Pharmaceuticals
- Lilly Ventures
- Linköping University
- Lurie Investment Fund
- MVM Life Science Partners
- MaRS Investment Accelerator Fund
- Majuven
- Makoto Life Sciences
- Mayo Clinic
- Medical Research Council
- Memorial Sloan Kettering Cancer Center
- Merck
- Meso Scale Discovery
- MiRx Pharmaceuticals
- Michael J. Fox Foundation
- Millennium Pharmaceuticals
- Miltenyi Biotec
- Mission Therapeutics
- Morningside Venture Investments
- Mount Sinai Hospital's Lunenfeld-Tanenbaum Research Institute
- Multiple Capital
- Natco Pharma
- National Cancer Institute
- National Institutes of Health Small Business Innovation Research
- New Enterprise Associates
- New Leaf Venture Partners
- New York University
- Nextech Invest
- Novartis Pharmaceuticals
- Novitas Capital
- Novus Biologics
- Nurix
- Nxt2b
- Ono Pharmaceutical
- Onyx Pharmaceuticals
- OrbiMed
- Osage University Partners
- Oxford Bioscience Partners
- Parkwalk Advisors
- Peloton Therapeutics
- Penn Pharmaceutical Services
- PerkinElmer
- Perrigo Company
- Perseus
- Pfizer
- Pharmascience
- Pharmion Corporation
- Priaxon
- Progenra
- Promega
- Proteologics
- Proteostasis Therapeutics
- Proteros Biostructures
- Providence Investment Company
- Quaker BioVentures
- Queen's University
- R & D Systems
- RA Capital Management
- Remeditex Ventures
- Rigel Pharmaceuticals
- Roche
- Roswell Park Cancer Institute
- SR One
- SV Life Sciences
- Sanofi
- Sanofi-Genzyme BioVentures
- Santa Cruze Biotech
- Scottish Investment Bank (Investment Arm of Scottish Enterprise)
- Selleckchem
- Sequoia Capital
- Servier
- Sidney Kimmel Comprehensive Cancer Center
- Sigma-Aldrich
- Sofinnova Ventures
- Statsyuk Research Group
- Stemgent
- Supergen
- Taiho Pharmaceutical
- Takeda
- Tensha Therapeutics
- TetraLogic Pharmaceuticals
- The Column Group
- Thermo Fisher Scientific
- Thiel Foundation's Breakout Labs
- Third Rock Ventures
- Tocris
- Tokyo Medical University
- UBP Biotech
- UbiQ Therapeutics
- Ubiquigent
- Universities of Toronto and Sherbrooke
- University of Birmingham
- University of Cambridge Enterprise
- University of Delaware
- University of Dundee
- University of Florida
- University of Glasgow
- University of Liverpool
- University of Michigan
- University of Oxford
- University of Rome Tor Vergata
- University of South Florida (USF)
- University of Texas
- University of Toronto
- Université de Montréal
- VenGrowth Capital Partners
- Vivolux
- Walter and Eliza Hall Institute of Medical Research
- Woodford Patient Capital Trust
- Wren Capital
- Yale University
- Yonsei University College of Medicine
- Yorkville Advisors
For more information about this report visit http://www.researchandmarkets.com/research/rpmgj4/ubiquitin
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article